| Abstract [eng] |
Probiotics have emerged as vital components in promoting health and preventing disease, particularly through their capacity to modulate the gut microbiota and produce bioactive compounds. Among these, tryptophan, a precursor to serotonin, plays a critical role in the gut-brain axis, influencing mood regulation, sleep, and overall mental health. Recent evidence highlights the potential of probiotic strains, such as Lactiplantibacillus plantarum and Lacticaseibacillus paracasei, to enhance tryptophan biosynthesis, offering therapeutic promise for conditions like depression, anxiety, and gastrointestinal disorders. However, natural limitations in bacterial metabolic pathways often restrict the production of such beneficial compounds. With the development of molecular engineering tools, such as the CRISPR-Cas9 system, the capacity to accurately alter bacterial genomes has been transformed. This research leverages CRISPR-Cas9 technology to construct an innovative plasmid system aimed at knocking out competing metabolic pathways in Lactobacillus strains, thereby enhancing tryptophan production. The study focuses on designing and assembling an engineered system to optimize the biosynthetic capabilities of these probiotic strains, addressing a significant gap in the field of microbial therapeutics. |
